What records are connected here?
- Evidence lanes
- 3
- Source years
- 3
- Drugs@FDA applications
- 1
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Smaller human trials
Rusfertide is a lab-made cyclic peptide that mimics hepcidin, the body’s iron-regulating hormone. It is the active ingredient in Mimrylo, which FDA approved in August 2026.1,2 Mimrylo is approved to treat excess red blood cells (erythrocytosis) in adults with polycythemia vera.1 In the randomized, placebo-controlled VERIFY trial of 293 adults described in the label, 77% of patients given rusfertide and 33% given placebo avoided becoming eligible for blood removal (phlebotomy) between weeks 20 and 32.1
| What it is | A synthetic cyclic peptide that mimics the hormone hepcidin, according to the Mimrylo label.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists Mimrylo, NDA 220605, with an original approval date of August 28, 2026. The cited label has no boxed warning.1,2 |
| Human evidence | One randomized, double-blind, placebo-controlled Phase 3 trial (VERIFY) in 293 adults with polycythemia vera, described in the label.1 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
Rusfertide is a synthetic cyclic peptide held together by a disulfide bond, with a fatty-acid chain attached, according to the label, which describes it as a hepcidin mimetic.1
In the United States it is the active ingredient of Mimrylo, approved under NDA 220605, according to Drugs@FDA.2
The label states that rusfertide mimics hepcidin and blocks ferroportin, the protein that moves iron out of cells. Less iron is then available to make red blood cells, which lowers hematocrit, the share of blood made up of red cells.1
VERIFY, described in the label, randomized 293 adults with polycythemia vera who needed frequent phlebotomy despite standard care to rusfertide or placebo for 32 weeks.1
Between weeks 20 and 32, 113 of 147 patients (77%) given rusfertide and 48 of 146 (33%) given placebo did not become eligible for phlebotomy, the trial’s measure of response, according to the label.1
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Yes. Drugs@FDA lists Mimrylo, application NDA 220605, with an original approval date of August 28, 2026.2
The Mimrylo label cited here (DailyMed SPL version 5, published November 11, 2026) states that it is indicated for the treatment of erythrocytosis in adults with polycythemia vera.1
The label has no boxed warning. Its warnings include new or worsening high platelet counts, local reactions where it is given and possible harm to a fetus based on animal data.1
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Rusfertide is not among them.3,4
Its longer-term effects: the randomized comparison with placebo described in the label lasted 32 weeks, after which patients could continue on open-label treatment.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Rusfertide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Rusfertide are a bounded selection, not every registration or paper about Rusfertide. For the years before Rusfertide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Rusfertide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Rusfertide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Mimrylo for erythrocytosis in polycythemia vera. In a randomized, placebo-controlled trial of 293 adults described in the label, more patients given rusfertide than placebo avoided becoming eligible for phlebotomy.↗↗
Status sources checked through November 15, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Mimrylo for erythrocytosis in polycythemia vera. In a randomized, placebo-controlled trial of 293 adults described in the label, more patients given rusfertide than placebo avoided becoming eligible for phlebotomy.↗↗
The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date October 31, 2026
Rusfertide for the treatment of polycythemia vera.↗Added to PeptideScanner November 16, 2026Literature metadata · added November 16, 2026
Rusfertide for the treatment of polycythemia vera.↗Source date October 31, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT05210790↗Source date October 19, 2026Literature metadata · added November 16, 2026
VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy.↗Source date October 13, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
5 of 5 selected trial records include at least one phase value; 5 of 5 include a status value in the retained structured contract.
5 of 5 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT04202965 at 2026-11-16T01:38:51.796Z. Its registry update date was 2025-08-20, and PeptideScanner's reviewed identity mapping was rusfertide.
PeptideScanner retained ClinicalTrials.gov record NCT04767802 at 2026-11-16T01:38:51.796Z. Its registry update date was 2024-03-18, and PeptideScanner's reviewed identity mapping was rusfertide.
PeptideScanner retained ClinicalTrials.gov record NCT05210790 at 2026-11-16T01:38:51.796Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was rusfertide.
5 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
Selected records span March 18, 2024 to October 31, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 42958870 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2026-10-31 (day precision). PeptideScanner associated the retained record with the identity slug rusfertide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05210790 at 2026-11-16T01:38:51.796Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was rusfertide.↗
Literature metadata
PubMed lists PMID 42868322 in Journal of clinical oncology : official journal of the American Society of Clinical Oncology as Journal Article, with publication-date metadata of 2026-10-13 (day precision). PeptideScanner associated the retained record with the identity slug rusfertide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07648030 at 2026-11-16T01:38:51.796Z. Its registry update date was 2026-10-02, and PeptideScanner's reviewed identity mapping was rusfertide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07765602 at 2026-11-16T01:38:51.796Z. Its registry update date was 2026-08-28, and PeptideScanner's reviewed identity mapping was rusfertide.↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for NDA 220605 with status AP dated 2026-08-28, and names rusfertide acetate among the application record's active ingredients.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04202965 at 2026-11-16T01:38:51.796Z. Its registry update date was 2025-08-20, and PeptideScanner's reviewed identity mapping was rusfertide.↗
Literature metadata
PubMed lists PMID 37863080 in The lancet. Gastroenterology & hepatology as Clinical Trial, Phase II, Multicenter Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-10-17 (day precision). PeptideScanner associated the retained record with the identity slug rusfertide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 38340748 in The lancet. Gastroenterology & hepatology as Letter, Comment, with publication-date metadata of 2024-03 (month precision). PeptideScanner associated the retained record with the identity slug rusfertide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 38340749 in The lancet. Gastroenterology & hepatology as Letter, Comment, with publication-date metadata of 2024-03 (month precision). PeptideScanner associated the retained record with the identity slug rusfertide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04767802 at 2026-11-16T01:38:51.796Z. Its registry update date was 2024-03-18, and PeptideScanner's reviewed identity mapping was rusfertide.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026